MedTrace Logo

Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis

NCT02958319 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 278

Last updated 2022-01-04

Study results available
· View outcomes & findings →

Summary

Patients with rheumatoid arthritis (RA) with positive antibodies against carbamylated proteins (anti-CarP) have a more severe clinical course. The primary objective of this study in adult subject with RA is as follows: To explore the clinical differences in activity indexes (Disease Activity Score of 28 joints with Erythro Sedimentaion Rate (DAS28-ESR)) at 6, 12 and 18 months of follow up according the anti-CarP antibodies status.

Conditions

Sponsors & Collaborators

  • Universidad Autonoma de Nuevo Leon

    lead OTHER

Principal Investigators

  • Jose Gerardo Garza Leal, PhD · Universidad Autónoma de Nuevo León

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-11-26
Completion
2018-11-26

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958319 on ClinicalTrials.gov